FILTER

LATEST INTERVIEWS

Mining
Peru

Luis Rivera

EXECUTIVE VICE PRESIDENT – AMERICAS, GOLD FIELDS
Gold Fields updates GBR on its Peruvian assets.
Mexico
Petrochemicals & Chemicals

Martín Fueyo

DIRECTOR GENERAL, AGRICULTURA NACIONAL S.A. DE C.V. (DRAGÓN)
Agricultura Nacional is relying on its laboratory research and collaboration with its clients for growth in Mexico.
Mining
DRC
MACIG

Oscar Siviwe

GENERAL MANAGER, TOP ENGINEERING SERVICES
Top Engineering Services offers local steel fabrication and engineering services for mines in DRC.
Mining
Peru

Guillaume Légaré

HEAD – SOUTH AMERICA, TORONTO STOCK EXCHANGE AND TSX VENTURE EXCHANGE
TSX and TSXV enjoyed an exciting year in 2020 with relation to Latin America, where C$2.9 billion equity capital was raised by companies that have mining projects in the region.
Mining
Chile

Alastair McIntyre

CEO, ALTIPLANO METALS
Altiplano updates GBR on progress at its Chilean assets.
United States
Pharma & Life Sciences

Scott Bluestein

CEO & CIO, HERCULES CAPITAL
Hercules Capital explains why it is well positioned to benefit from a thriving life sciences and technology scene.
United States
Pharma & Life Sciences

James Sapirstein

PRESIDENT & CEO, AZURRX BIOPHARMA
AzurRx Biopharma has benefitted from the availability of financing to expand its pipeline.
Mining
Chile

Alejandra Fernandez

MINING DIRECTOR, FITCH RATINGS
Fitch Ratings in Chile speaks to GBR about the prospects for the country’s mining industry.
Mining
Canada

Stuart Lister & Maarten van Koppen

VICE PRESIDENT OF MARKETING & COMMUNICATIONS & PRODUCT MANAGER-MINE OPERATIONS, MACLEAN ENGINEERING
Maclean Engineering explains how interoperability of electric mining equipments offers the best chance for sustainable and profitable mining into the future.
Petrochemicals & Chemicals
India

Roma Shah & Komal Doshi

CEO & DIRECTOR, EASTMEN CHEMICALS
Eastmen Chemicals is set on increasing its market beyond India.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL